Press Releases

27/09/2023 OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

20/09/2023 OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences

11/09/2023 OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology

02/08/2023 OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics

12/07/2023 OSE Immunotherapeutics Announces Publication in Frontiers in Immunology on OSE-230, its Novel Agonist Therapy in Chronic Inflammation

11/07/2023 OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

06/07/2023 OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis; Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the Treatment of Acute Lymphoblastic Leukemia.

04/07/2023 OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment

22/06/2023 OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder’s Meeting

20/06/2023 OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer

15/06/2023 OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation at International Conferences

06/06/2023 OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting Tedopi® is the Company’s Most Advanced Product in Clinical Development

31/05/2023 OSE Immunotherapeutics’ Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director Ahead of the General Shareholders’ Meeting of June 22, 2023

24/05/2023 OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi® in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIGE 63 trial)

12/05/2023 OSE Immunotherapeutics to Continue the Clinical Development in Ulcerative Colitis with Full Rights to Lusvertikimab

27/04/2023 OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update

20/04/2023 OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology at the 2023 American Association for Cancer Research (AACR) Annual Meeting

18/04/2023 OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio at the 2023 American Association for Cancer Research Annual Meeting

1 2 3 4 5 6 7 8 9 10 11 12 13 14